Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

BackgroundThe COMPASSION-15 trial demonstrated that cadonilimab plus chemotherapy (CAD-CHM) confers clinical benefits over placebo plus chemotherapy (PLA-CHM) as a first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhifeng Zhou, Yanqing Yang, Shaofang Chen, Maojin You
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Immunology
Subjects:	cadonilimab chemotherapy cost-effectiveness first-line treatment HER2-negative gastric or gastroesophageal junction adenocarcinoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1575627/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01)

Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialResearch in context
by: Zhi Peng, et al.
Published: (2025-09-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials
by: Yuxuan Lin, et al.
Published: (2025-05-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review
by: Tao Wang, et al.
Published: (2025-03-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome
by: LI Hao, DENG Jin, LIU Peihua, ZHANG Quanyong, CAI Zhai
Published: (2025-06-01)

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration
by: Du Feng, et al.
Published: (2024-12-01)

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
by: Panpan Zhang, et al.
Published: (2018-09-01)

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Digital pathology-based artificial intelligence model to predict microsatellite instability in gastroesophageal junction adenocarcinomas
by: Zhenqian Li, et al.
Published: (2025-08-01)

Laparoscopic curative resection following perioperative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel and its influence on Claudin18.2 expression in advanced gastric or gastroesophageal junction adenocarcinoma: a two-case report
by: Tohru Takahashi, et al.
Published: (2025-04-01)

Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy in gastric cancer and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of single-arm studies
by: Jun Leng, et al.
Published: (2025-08-01)

DNA methylation markers for sensitive detection of circulating tumor DNA in patients with gastroesophageal cancers
by: N. Øgaard, et al.
Published: (2024-12-01)

A conceptual model for advanced/metastatic gastric or gastroesophageal junction cancer: a review of qualitative studies and results from patient interviews
by: France Ginchereau Sowell, et al.
Published: (2025-01-01)

Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes
by: Penghui Liu, et al.
Published: (2025-08-01)

Kyoto International Consensus Report on Anatomy, Pathophysiology and Clinical Significance of the Gastroesophageal Junction
by: A. A. Sheptulin, et al.
Published: (2023-12-01)

A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
by: Haijuan Yu, et al.
Published: (2024-11-01)

Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: a systematic review and meta-analysis
by: Xiaoying Ji, et al.
Published: (2025-03-01)

Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01)

Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis
by: Yunnan Zhang, et al.
Published: (2025-04-01)

Primary malignant melanoma of the gastroesophageal junction with KIT gene exon 11 mutation
by: Xiaozhuo Gao, et al.
Published: (2024-06-01)

Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials
by: Xinming Lei, et al.
Published: (2024-11-01)

Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
by: Samaneh Salarvand, et al.
Published: (2025-08-01)

Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Shixian Liu, et al.
Published: (2025-08-01)

Deciphering the dual role of autophagy in gastric cancer and gastroesophageal junction cancer: from tumor suppression to cancer progression
by: Lili Lei, et al.
Published: (2025-06-01)

Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results
by: M. V. Sedova, et al.
Published: (2023-09-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Clinical efficacy and safety of Cadonilimab in the treatment of advanced gynecological malignancies: a retrospective, real-world study
by: Yisidan Huang, et al.
Published: (2025-08-01)

Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
by: Saiqa Nisar, et al.
Published: (2024-10-01)

Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study
by: Yidi Liang, et al.
Published: (2025-06-01)

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
by: K. Nakanishi, et al.
Published: (2025-06-01)

Evaluation of Conventional Treatment Planning Techniques for Radiotherapy of Gastroesophageal Junction Cancer: A Dosimetric Comparison between Male and Female Patients
by: Mohamad Pursamimi, et al.
Published: (2025-03-01)

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
by: Yiling Ding, et al.
Published: (2025-12-01)

Eligibility and workload implications of adjuvant immunotherapy in patients with resected esophageal and gastroesophageal junction (ESO/GEJ) cancer
by: T.H. Lee, et al.
Published: (2025-03-01)